Fresenius Medical Care Corporation (NYSE:FMS) is set to announce third quarter earning results on Thursday 29th October 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, FMS to report 3Q20 income of $ 0.64 per share.
For the full year, analysts anticipate top line of $ 21546.20 million, while looking forward to income of $ 3.79 per share bottom line.
Previous Quarter Performance
Fresenius Medical Care Corporation came out with income for the second quarter of $ 0.66 per share, from the revenue of $ 5,019.00 million. The quarterly earnings developed 29.41 percent while revenues elevated 7.98 percent compared with the same quarter last year.
Wall street analysts are predicting, FMS to report 2Q20 income of $ 0.62 per share from revenue of $ 5403.29 million. The bottom line results beat street analysts by $ 0.04 or 6.45 percent, at the same time, top line results fell short of analysts by $ 384.29 million or 7.11 percent.
Stock Performance
Shares of Fresenius Medical Care Corporation traded low $ -1.12 or -2.73 percent on Wednesday, reaching $ 39.88 with volume of 1.95 million shares. Fresenius Medical Care Corporation has traded high as $ 40.40 and has cracked $ 39.72 on the downward trend
According to the previous trading day, closing price of $ 39.88, representing a 40.56 % increase from the 52 week low of $ 29.17 and a 11.92 % decrease over the 52 week high of $ 46.55.
The company has a market capital of $ 24.30 billion and is part of the Healthcare sector and Medical Care industry.
Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patients residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
